Novacyt S.A. (AIM:NCYT)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 30.39M +10.4% |
| Revenue (ttm) | 20.03M +2.0% |
| Net Income | -22.88M |
| EPS | -0.32 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,480,186 |
| Average Volume | 248,518 |
| Open | 43.50 |
| Previous Close | 42.30 |
| Day's Range | 43.10 - 65.20 |
| 52-Week Range | 26.60 - 65.20 |
| Beta | n/a |
| RSI | 78.08 |
| Earnings Date | Apr 30, 2026 |
About Novacyt
Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the... [Read more]
Financial Performance
In 2025, Novacyt's revenue was 20.03 million, an increase of 2.03% compared to the previous year's 19.63 million. Losses were -22.88 million, -45.20% less than in 2024.
Financial StatementsNews
AIM Market Roundup: Pacsco, Deltic Energy, Novacyt
Pacsco, Deltic Energy, Novacyt are today's top risers, while Southern Energy, Sutton Harbour take the biggest fall on London's AIM market
Novacyt Earnings Call Transcript: H2 2025
Revenue grew 4% year-on-year to GBP 20 million, with strong gross margins and reduced losses. Strategic R&D investment and the Southern Cross acquisition are driving growth, with double-digit revenue expansion targeted for 2026 and a solid cash position supporting profitability goals.
Novacyt Transcript: Status update
Acquisition of Southern Cross Diagnostics accelerates growth, profitability, and product expansion, with immediate accretive impact and direct access to key customers in Australia and New Zealand. Capital raise was oversubscribed, strengthening the balance sheet and supporting future product launches and partnerships.
Novacyt Earnings Call Transcript: H2 2024
Major operational consolidation and cost reductions delivered GBP 8 million in savings, with strong growth in reproductive healthcare and a stabilized high-margin research segment. Cash reserves remain robust, supporting increased R&D investment and a confident outlook for profitability.
Novacyt Earnings Call Transcript: H1 2024
Double-digit growth in core reproductive health products and a GBP 7 million cash boost from DHSC dispute resolution have strengthened the financial position. Integration of Yourgene is ahead of schedule, with cost savings and R&D investment supporting future growth.
Novacyt Earnings Call Transcript: H2 2023
Novacyt Earnings Call Transcript: H1 2023
Novacyt Earnings Call Transcript: H2 2022
Novacyt Earnings Call Transcript: H1 2022
Novacyt S.A. ("Novacyt", the "Company" or the "Group"): Half Year 2022 Results
PARIS & CAMBERLEY, England--(BUSINESS WIRE)--Regulatory News: Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its unaudited results for the ...